Malignant Pleural Mesothelioma, Advanced
Conditions
Keywords
Malignant Pleural Mesothelioma, Advanced, Oncolytic Adenovirus, Programmed Death Receptor
Brief summary
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.
Detailed description
By monitoring the clinical symptoms of patients with advanced immune resistant pleural mesothelioma treated with adenovirus injection combined with programmed death receptor (PD-1) inhibitors, we analyze and explore the effectiveness and safety of using oncolytic virus drugs. Exploring the influencing factors of using oncolytic adenovirus injection combined with PD-1 inhibitors to reverse immune resistance in MPM patients. Evaluate the safety of the drug, and finally evaluate the quality of life of patients using oncolytic adenovirus injection(H101) combined with PD-1 inhibitors.
Interventions
DRUGOncolytic Adenovirus H101
The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
DRUGProgrammed death receptor-1 inhibitor
The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Sponsors
Tianjin Medical University Second Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years old (including boundary values), regardless of gender. 2. Confirmed as late stage MPM patients who have failed immunotherapy. 3. The patient or their legal representative can understand and sign the informed consent form. 4. At least one lesion that can safely undergo intratumoral injection or intrapleural injection of oncolytic adenovirus as the target lesion, with a diameter of spiral CT ≥ 1cm or ordinary CT ≥ 2cm, and can be measured through imaging methods. 5. ECOG score 0-2.
Exclusion criteria
1. Physicians participating in the study believe that patients may not be able to provide continuous follow-up information. 2. Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases). 3. Contraindications to relevant drugs (such as oncolytic adenoviruses, PD-1 inhibitors, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR(Objective Response Rate) | 36 months | The proportion of CR(complete response) and PR(partial response) in all patients. |
| DCR(Disease Control Rate) | 36 months | The proportion of CR(complete response), PR(partial response) and SD(stable disease) in all patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS(Progression Free Survival) | 36 months | Refers to the time from the first treatment day to the first occurrence of disease progression or death from any cause (whichever occurs first), and the end point event is determined by the investigator according to RECIST version1.1. |
| OS(Overall Survival) | 36 months | Time between the date of grouping and death from any cause or the end of the last follow-up visit. |
| AEs(Adverse Events) | 36 months | Toxicity were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. All serious and non-serious adverse events that occur after enrollment through 30 (+7) days after the last administration of H101 will be recorded. |
Countries
China
Contacts
Primary ContactHaitao Wang, Ph.D
Backup ContactJinhuan Wang, Ph.D
Outcome results
None listed